Cited by 447Acute Myeloid Leukemia ResearchCancer Genomics and DiagnosticsChronic Myeloid Leukemia Treatments

The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.

Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia

Open access

McMahon, Christine M., Ferng, Timothy, Canaani, Jonathan, Wang, Eunice S., Morrissette, Jennifer J.D., Eastburn, Dennis J., Pellegrino, Maurizio, Durruthy-Durruthy, Robert, Watt, Christopher D., Asthana, Saurabh, Lasater, Elisabeth A., DeFilippis, RosaAnna, Peretz, Cheryl A.C., McGary, Lisa H.F., Deihimi, Safoora, Logan, Aaron C., Luger, Selina M., Shah, Neil P., Carroll, Martin, Smith, Catherine C., Perl, Alexander E.·2019·Cancer Discovery

DOI 10.1158/2159-8290.cd-18-1453PMC PMC11994087

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clinical efficacy in relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however, gilteritinib is not curative, and response duration is limited by the development of secondary resistance. To evaluate resistance mechanisms, we analyzed baseline and progression samples from patients treated on clinical trials of gilteritinib. Targeted next-generation sequencing at the time of AML progression on gilteritinib identified treatment-emergent mutations that activate RAS/MAPK pathway signaling, most commonly in NRAS or KRAS. Less frequently, secondary FLT3-F691L gatekeeper mutations or BCR–ABL1 fusions were identified at progression. Single-cell targeted DNA sequencing revealed diverse patterns of clonal selection and evolution in response to FLT3 inhibition, including the emergence of RAS mutations in FLT3-mutated subclones, the expansion of alternative wild-type FLT3 subclones, or both patterns simultaneously. These data illustrate dynamic and complex changes in clonal architecture underlying response and resistance to mutation-selective tyrosine kinase inhibitor therapy in AML. Significance: Comprehensive serial genotyping of AML specimens from patients treated with the selective FLT3 inhibitor gilteritinib demonstrates that complex, heterogeneous patterns of clonal selection and evolution mediate clinical resistance to tyrosine kinase inhibition in FLT3-mutated AML. Our data support the development of combinatorial targeted therapeutic approaches for advanced AML. See related commentary by Wei and Roberts, p. 998. This article is highlighted in the In This Issue feature, p. 983

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-18-1453

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Clonal Evolution of Tumor Cell Populations: Acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression.
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
Grimwade, D. J., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., & Burnett, A. K. (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,936
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611
The origin and evolution of mutations in acute myeloid leukemia
Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.023 · Cited by 1,575
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Yamamoto, Y. (2001) · Blood · doi:10.1182/blood.v97.8.2434 · Cited by 1,152
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm
Fröhling, S., Schlenk, R. F., Breitruck, J., Benner, A., Kreitmeier, S., Tobis, K., Döhner, H., & Döhner, K. (2002) · Blood · doi:10.1182/blood-2002-05-1440 · Cited by 873
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Smith, C. C., Wang, Q., Chin, C.-S., Salerno, S. N., Damon, L. E., Levis, M. J., Perl, A. E., Travers, K. J., Wang, S., Hunt, J. P., et al. (2012) · Nature · doi:10.1038/nature11016 · Cited by 738
Self-citation

Flagged first, then by citations

Show all 35 references

1 of the 35 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Cortes, 2018, Quizartinib significantly prolongs overall survival in patients with FLT3-internal tandem duplication–mutated relapsed/refractory AML in the phase 3, randomized, controlled QuANTUM-R trial [abstract]

Sorted by citations

Items 101–200 of 447

Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease
Jen, W., Kantarjian, H. M., Kadia, T. M., Dinardo, C. D., Issa, G. C., Short, N. J., Yilmaz, M. E., Borthakur, G. M., Ravandi, F., & Daver, N. G. (2024) · British Journal of Haematology · doi:10.1111/bjh.19519 · Cited by 38
Overcoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure
Capelli, D., Menotti, D., Fiorentini, A., Saraceni, F., & Olivieri, A. (2022) · Cancers · doi:10.3390/cancers14174315 · Cited by 36
TP-0903 is active in models of drug-resistant acute myeloid leukemia
Jeon, J. Y., Buelow, D. R., Garrison, D. A., Niu, M., Eisenmann, E. D., Huang, K. M., Thomas, M. E. Z., Weber, R. H., Whatcott, C. J., Warner, S. L., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140169 · Cited by 35
Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells
Kawashima, N., Ishikawa, Y., Kim, J. H., Ushijima, Y., Akashi, A., Yamaguchi, Y., Hattori, H., Nakashima, M., Ikeno, S., Kihara, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29304-6 · Cited by 38
Genetic heterogeneity and clonal evolution in acute myeloid leukemia
Romer-Seibert, J. S., & Meyer, S. E. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000626 · Cited by 33
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia
Post, S. M., Ma, H., Malaney, P., Zhang, X., Aitken, M. J. L., Mak, P. Y., Ruvolo, V. R., Yasuhiro, T., Kozaki, R., Chan, L. E., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278369 · Cited by 33
New Therapeutic Strategies for Adult Acute Myeloid Leukemia
Ishii, H., & Yano, S. (2022) · Cancers · doi:10.3390/cancers14112806 · Cited by 33
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG
Loo, S., Roberts, A. W., Anstee, N. S., Kennedy, G., He, S., Schwarer, A. P., Enjeti, A. K., D’Rozario, J., Marlton, P. V., Bilmon, I., et al. (2023) · Blood · doi:10.1182/blood.2023020301 · Cited by 32
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes
Rivera, D., Kim, K., Kanagal‐Shamanna, R., Borthakur, G. M., Bravo, G. M., Daver, N. G., Dinardo, C. D., Short, N. J., Yilmaz, M. E., Pemmaraju, N., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26731 · Cited by 32
Resistance to targeted therapies in acute myeloid leukemia
Mecklenbrauck, R., & Heuser, M. (2022) · Clinical & Experimental Metastasis · doi:10.1007/s10585-022-10189-0 · Cited by 31
Multidrug Resistance in Cancer Cells: Focus on a Possible Strategy Plan to Address Colon Carcinoma Cells
Karthika, C., Sureshkumar, R., Zehravi, M., Akter, R., Ali, F., Ramproshad, S., Mondal, B., Kundu, M. K., Dey, A., Rahman, M. H., et al. (2022) · Life · doi:10.3390/life12060811 · Cited by 30
FLT3-targeted treatment for acute myeloid leukemia
Arai, Y., Chi, S., Minami, Y., & Yanada, M. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03374-0 · Cited by 30
Developments and challenges of FLT3 inhibitors in acute myeloid leukemia
Ge, S., Liu, S., & Xue, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.996438 · Cited by 30
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
Dumas, P., Raffoux, E., Bérard, E., Bertoli, S., Heiblig, M., Desbrosses, Y., Bonmati, C., Pautas, C., Lambert, J., Orvain, C., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01742-7 · Cited by 34
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Venditti, A., Palmieri, R., Maurillo, L., Röllig, C., Wierzbowska, A., de Leeuw, D. C., Efficace, F., Curti, A., Ngai, L. L., Tettero, J. M., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024013744 · Cited by 32
Self-citation
Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication
Tiong, I. S., & Loo, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054790 · Cited by 30
Clonal competition within complex evolutionary hierarchies shapes AML over time
Sandén, C., Lilljebjörn, H., Orsmark‐Pietras, C., Henningsson, R., Saba, K. H., Landberg, N., Thorsson, H., von Palffy, S., Peña‐Martínez, P., Högberg, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14106-0 · Cited by 30
Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia
Zhang, Z., Huang, J., Zhang, Z., Shen, H., Tang, X., Wu, D., Bao, X., Xu, G., & Chen, S. (2024) · Biomarker Research · doi:10.1186/s40364-024-00600-1 · Cited by 30
The transcriptional regulation of normal and malignant blood cell development
Edginton‐White, B., & Bonifer, C. (2021) · FEBS Journal · doi:10.1111/febs.15735 · Cited by 27
Single-cell sequencing technology in tumor research
Bai, X., Li, Y., Zeng, X., Zhao, Q., & Zhang, Z. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.03.013 · Cited by 30
RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia
Decroocq, J., Birsen, R., Montersino, C., Chaskar, P., Mano, J., Poulain, L., Friedrich, C., Alary, A., Guermouche, H., Sahal, A., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01541-0 · Cited by 30
FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia
Tan, Y., Xin, L., Wang, Q., Xu, R., Tong, X., Chen, G., Ma, L., Yang, F., Jiang, H., Zhang, N., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216933 · Cited by 27
Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series
Alotaibi, A. S., Yilmaz, M. E., Loghavi, S., Dinardo, C. D., Borthakur, G. M., Kadia, T. M., Thakral, B., Pemmaraju, N., Issa, G. C., Konopleva, M. Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.588876 · Cited by 27
Clonal Architecture and Evolutionary Dynamics in Acute Myeloid Leukemias
Duchmann, M., Laplane, L., & Itzykson, R. (2021) · Cancers · doi:10.3390/cancers13194887 · Cited by 31
The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy
Lee, J. Y., Kannan, B., Lim, B. Y., Li, Z., Lim, A. H., Loh, J. W., Ko, T. K., Ng, C. C. Y., & Chan, J. Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147839 · Cited by 29
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia
Zhou, W., Yu, J., Li, Y., & Wang, K. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00353-3 · Cited by 27
Clonal evolution and hierarchy in myeloid malignancies
Takahashi, K., & Tanaka, T. N. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.05.004 · Cited by 28
Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia
Pino, J. C., Posso, C., Joshi, S. K., Nestor, M. D., Moon, J., Hansen, J., Hutchinson-Bunch, C. M., Gritsenko, M., Weitz, K., Watanabe‐Smith, K., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101359 · Cited by 26
Application of high-throughput single-nucleus DNA sequencing in pancreatic cancer
Zhang, H., Karnoub, E.-R. R., Umeda, S., Chaligné, R., Masilionis, I., McIntyre, C. A., Sashittal, P., Hayashi, A., Zucker, A., Mullen, K. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36344-z · Cited by 24
Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3-Mutated AML Patients
Molica, M., Perrone, S., & Rossi, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113647 · Cited by 26
The Role of Somatic Mutations in Acute Myeloid Leukemia PathogenesisPreprint
Kishtagari, A., & Levine, R. L. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034975 · Cited by 26
Aptamers against cancer drug resistance: Small fighters switching tactics in the face of defeat
Sanati, M., Afshari, A. R., Ahmadi, S. S., Kesharwani, P., & Sahebkar, A. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166720 · Cited by 27
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia
Levis, M. J., Perl, A. E., Schiller, G. J., Fathi, A. T., Roboz, G. J., Wang, E. S., Altman, J. K., Rajkhowa, T., Ando, M., Suzuki, T., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023010619 · Cited by 25
Self-citation
How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?
Perrone, S., Ottone, T., Zhdanovskaya, N., & Molica, M. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.130 · Cited by 26
FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review
Abdel‐Aziz, A. K., Dokla, E. M. E., & Saadeldin, M. K. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104139 · Cited by 24
Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy
Cerrano, M., Duchmann, M., Kim, R., Vasseur, L., Hirsch, P., Thomas, X., Quentin, S., Pasanisi, J., Passet, M., Rabian, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0932-8 · Cited by 24
The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML
Charlet, A., Kappenstein, M., Keye, P., Kläsener, K., Endres, C., Poggio, T., Gorantla, S. P., Kreutmair, S., Sänger, J., Illert, A. L., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01462-4 · Cited by 24
Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia
Ciotti, G., Marconi, G., & Martinelli, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.810387 · Cited by 23
Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML
Yamatani, K., Ai, T., Saito, K., Suzuki, K., Hori, A., Kinjo, S., Ikeo, K., Ruvolo, V. R., Zhang, W., Mak, P. Y., et al. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101354 · Cited by 22
Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
Zhang, Y., Wang, P., Wang, Y., & Shen, Y. (2023) · Biomarker Research · doi:10.1186/s40364-022-00447-4 · Cited by 22
Monitoring of Leukemia Clones in B-cell Acute Lymphoblastic Leukemia at Diagnosis and During Treatment by Single-cell DNA Amplicon Sequencing
Meyers, S., Servera, L. A., Gielen, O., Erard, M., Swings, T., Bie, J. D., Michaux, L., Dewaele, B., Boeckx, N., Uyttebroeck, A., et al. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000700 · Cited by 21
Single-cell methods in myeloproliferative neoplasms: old questions, new technologies
O’Sullivan, J., Mead, A. J., & Psaila, B. (2022) · Blood · doi:10.1182/blood.2021014668 · Cited by 24
FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile
Garciaz, S., & Hospital, M. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s236740 · Cited by 21
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives
Orgueira, A. M., Pérez, L. B., Torre, A. M., Raíndo, A. P., López, M. C., Arias, J. Á. D., Ferro, R. F., Rodríguez, B. A., González, M. S., Ferreiro, M. A., et al. (2020) · Minerva Medica · doi:10.23736/s0026-4806.20.06989-x · Cited by 21
Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance
Lachowiez, C. A., Dinardo, C. D., & Loghavi, S. (2023) · Cancers · doi:10.3390/cancers15051617 · Cited by 20
Microfluidic design in single-cell sequencing and application to cancer precision medicine
Han, X., Xu, X. J., Yang, C. J., & Liu, G. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100591 · Cited by 21
Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach
Yen, S., Chen, L., Huang, H.-L., HuangFu, W., Chen, Y.-Y., Lin, T. E., Lien, S.-T., Tseng, H.-J., Sung, T.-Y., Hsieh, J., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105675 · Cited by 20
A novel lncRNA SNHG29 regulates EP300- related histone acetylation modification and inhibits FLT3-ITD AML development
Liu, S., Zhou, J. H. S., Ye, X., Chen, D., Chen, W., Lin, Y., Chen, Z., Chen, B., & Shang, J. (2023) · Leukemia · doi:10.1038/s41375-023-01923-y · Cited by 20
FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia
Sung, P. J., Selvam, M., Riedel, S. S., Xie, H. M., Bryant, K. M., Manning, B. S., Wertheim, G. B. W., Kulej, K., Pham, L., Bowman, R. L., et al. (2024) · Leukemia · doi:10.1038/s41375-023-02131-4 · Cited by 20
Self-citation
Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia
McMahon, C. M., & Perl, A. E. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1657009 · Cited by 20
Self-citation
FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review
Loschi, M. L., Sammut, R., Chiche, E., & Cluzeau, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115873 · Cited by 20
Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents
Halik, A., Arends, C. M., Bullinger, L., Damm, F., & Frick, M. (2022) · Cancers · doi:10.3390/cancers14071689 · Cited by 20
Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development
Lv, M., Hu, W., Zhang, S., He, L., Hu, C., & Yang, S. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215716 · Cited by 19
Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia
Wang, J., Tomlinson, B. K., & Lazarus, H. M. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01090-3 · Cited by 18
Cytogenetics and genomics of acute myeloid leukemia
Snaith, O., Poveda-Rogers, C., Laczko, D. I., Yang, G., & Morrissette, J. J. D. (2023) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2023.101533 · Cited by 23
Self-citation
Single-cell sequencing in hematology
Brierley, C. K., & Mead, A. J. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000613 · Cited by 19
Targeted Single-Cell RNA and DNA Sequencing With Fluorescence-Activated Droplet Merger
Clark, I. C., Delley, C. L., Sun, C., Thakur, R. A., Stott, S. L., Thaploo, S., Li, Z., Quintana, F. J., & Abate, A. R. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c03059 · Cited by 19
Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation
Khoury, J. D., Tashakori, M., Yang, H. Y., Loghavi, S., Wang, Y., Wang, J., Piya, S., & Borthakur, G. M. (2020) · Cancers · doi:10.3390/cancers12123511 · Cited by 19
Oncogenic N-Ras Mitigates Oxidative Stress–Induced Apoptosis of Hematopoietic Stem Cells
Ney, G. M., Yang, K. B., Ng, V., Liu, L., Zhao, M., Kuk, W., Alaka, L., Sampang, L., Ross, A., Jones, M. A., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-0118 · Cited by 19
Momelotinib is a highly potent inhibitor of FLT3-mutant AML
Azhar, M., Kincaid, Z., Kesarwani, M., Ahmed, A., Wunderlich, M., Latif, T., Starczynowski, D. T., & Azam, M. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004611 · Cited by 19
Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy
Song, F., Lin, S., Xu, T., Yang, C., Sharavyn, B., Naranmandura, H., Zhang, Y., & Huang, P. C. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101286 · Cited by 21
Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies
Achi, H. E., & Kanagal‐Shamanna, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.748250 · Cited by 21
BMX kinase mediates gilteritinib resistance in FLT3 -mutated AML through microenvironmental factors
Buelow, D. R., Bhatnagar, B., Orwick, S. J., Jeon, J. Y., Eisenmann, E. D., Stromatt, J. C., Pabla, N., Blachly, J. S., Baker, S. D., & Blaser, B. W. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007952 · Cited by 19
From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia
Gurnari, C., Voso, M. T., Maciejewski, J. P., & Visconte, V. (2020) · Cancers · doi:10.3390/cancers12020357 · Cited by 18
Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia
Chi, S., & Minami, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042362 · Cited by 16
Which FLT3 Inhibitor for Treatment of AML?
Senapati, J., & Kadia, T. M. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00952-6 · Cited by 18
Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia
Brinton, L. T., Sher, S., Williams, K., Canfield, D., Orwick, S. J., Wasmuth, R., Cempre, C. B., Skinner, J. N., Lehman, A., Blachly, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12061574 · Cited by 18
Overcoming Secondary Mutations of Type II Kinase Inhibitors
Wang, X., DeFilippis, R. A., Yan, W., Shah, N. P., & Li, H. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01629 · Cited by 18
Self-citation
The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy
Ball, B. J., Hsu, M., Devlin, S. M., Arcila, M. E., Roshal, M., Zhang, Y., Famulare, C., Goldberg, A. D., Cai, S. F., Dunbar, A. J., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26146 · Cited by 17
FLT3 targeting in the modern era: from clonal selection to combination therapies
Kennedy, V. E., & Smith, C. C. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03681-0 · Cited by 17
Self-citation
Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
Modak, R. V., Rebola, K. G. D. O., McClatchy, J., Mohammadhosseini, M., Damnernsawad, A., Kurtz, S. E., Eide, C. A., Wu, G., Laderas, T., Nechiporuk, T., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2654 · Cited by 18
A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
Lee, L., Hizukuri, Y., Severson, P. L., Powell, B., Zhang, C., Ma, Y., Narahara, M., Sumi, H., Hernandez, D., Rajkhowa, T., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.247346 · Cited by 17
A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance
Joshi, S. K., Sharzehi, S., Pittsenbarger, J., Bottomly, D., Tognon, C. E., McWeeney, S. K., Druker, B. J., & Traer, E. A. (2021) · American Journal of Hematology · doi:10.1002/ajh.26174 · Cited by 17
5-Demethylnobiletin Inhibits Cell Proliferation, Downregulates ID1 Expression, Modulates the NF-κB/TNF-α Pathway and Exerts Antileukemic Effects in AML Cells
Chen, P., Wang, C., Tsao, E.-C., Chen, Y., Wu, M., Ho, C., & Yen, J.-H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137392 · Cited by 17
Fusion oncoproteins and cooperating mutations define disease phenotypes in NUP98 -rearranged leukemia
Umeda, M., Hiltenbrand, R., Michmerhuizen, N. L., Barajas, J. M., Thomas, M. E., Arthur, B., Walsh, M. P., Song, G., Ma, J., Westover, T., et al. (2025) · Blood · doi:10.1182/blood.2025028993 · Cited by 16
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
Pratz, K. W., Kaplan, J. B., Levy, M. Y., Bixby, D. L., Burke, P. W., Erba, H. P., Wise-Draper, T. M., Roboz, G. J., Papadantonakis, N., Rajkhowa, T., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.281216 · Cited by 16
Methyltransferase DNMT3B in leukemia
Zhang, H., Ying, H., & Wang, X. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1666377 · Cited by 16
CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-β Signaling
Kim, B.-R., Jung, S., Han, A., Park, G., Kim, H., Yuan, B., Battula, V. L., Andreeff, M., Konopleva, M. Y., Chung, Y., et al. (2020) · Cancers · doi:10.3390/cancers12071737 · Cited by 16
Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Smith, C. C., Viny, A. D., Massi, E., Kandoth, C., Socci, N. D., Rapaport, F., Najm, M., Medina-Martinez, J. S., Papaemmanuil, E., Tarver, T. C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3458 · Cited by 17
Self-citation
Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia
Lang, T. J. L., Damm, F., Bullinger, L., & Frick, M. (2023) · Cancers · doi:10.3390/cancers15184573 · Cited by 16
Recent advancements in biomarkers, therapeutics, and associated challenges in acute myeloid leukemia
Prajapati, S. K., Neha, K., Bhowmik, D., & Gupta, R. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05963-x · Cited by 15
Advances in the pathogenesis of FLT3-mutated acute myeloid leukemia and targeted treatments
Travaglini, S., Gurnari, C., Ottone, T., & Voso, M. T. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001094 · Cited by 15
FGFR Signaling as a Candidate Therapeutic Target for Cancers Resistant to Carbon Ion Radiotherapy
Darwis, N. D. M., Nachankar, A., Sasaki, Y., Matsui, T., Noda, S., Murata, K., Tamaki, T., Ando, K., Okonogi, N., Shiba, S., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184563 · Cited by 15
Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia
Ahmadmehrabi, K., Haque, A. R., Aleem, A., Griffiths, E. A., & Roloff, G. W. (2021) · Cancers · doi:10.3390/cancers13184646 · Cited by 14
A precision medicine classification for treatment of acute myeloid leukemia in older patients
Mims, A. S., Kohlschmidt, J., Borate, U., Blachly, J. S., Orwick, S. J., Eisfeld, A., Papaioannou, D., Nicolet, D., Mrózek, K., Stein, E. M., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01110-5 · Cited by 14
Self-citation
Proliferation and Self-Renewal Are Differentially Sensitive to NRASG12V Oncogene Levels in an Acute Myeloid Leukemia Cell Line
Kurata, M., Antony, M. L., Noble-Orcutt, K. E., Rathe, S. K., Lee, Y., Furuno, H., Ishibashi, S., Ikeda, M., Yamamoto, K., Kitagawa, M., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0109 · Cited by 14
Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3‐ITD positive AML
Miyajima, T., Onozawa, M., Yoshida, S. Y., Miyashita, N., Kimura, H., Takahashi, S., Yokoyama, S., Matsukawa, T., Goto, H., Sugita, J., et al. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14055 · Cited by 14
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial
Konopleva, M. Y., Dail, M., Daver, N. G., Garcia, J. S., Jonas, B. A., Yee, K. W. L., Kelly, K. R., Vey, N., Assouline, S. E., Roboz, G. J., et al. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.01.007 · Cited by 14
A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia
Mohebbi, A., Shahriyary, F., Farrokhi, V., Bandar, B., & Saki, N. (2024) · Leukemia Research · doi:10.1016/j.leukres.2024.107505 · Cited by 14
Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations
Wei, T., Wang, Z., Lu, M., Xu, Y., Yang, J., Ni, X.-F., Yang, C., Zhang, M., Liu, J., Li, Q., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00529 · Cited by 14
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia
Eisfelder, B. J., Saygin, C., Wynne, J. P., Cove, M. C., Fischietti, M., Beauchamp, E. M., Cheng, J. X., Odenike, O. M., Roboz, G. J., Alachkar, H., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00433-3 · Cited by 14
Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemia
Kropp, E. M., & Li, Q. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.04.001 · Cited by 14
Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML
Popescu, B. O., Stahlhut, C. E., Tarver, T. C., Wishner, S., Lee, B. J., Peretz, C. A. C., Luck, C., Phojanakong, P. J., Cámara, J. A., Hongo, H., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101290 · Cited by 12
Self-citation
Therapeutic biomarkers in acute myeloid leukemia: functional and genomic approaches
Bhatia, K. S., Sandhu, V., Wong, M. H., Iyer, P., & Bhatt, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1275251 · Cited by 13
Targeting FLT3 for treating diseases: FLT3 inhibitors
Rong, Q.-Y., Lu, Y., Zhang, W., Rao, G.-W., & Zheng, Q. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104367 · Cited by 13
The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia
Altman, J. K., Perl, A. E., Hill, J. E., Rosales, M., Bahceci, E., & Levis, M. J. (2020) · Cancer Medicine · doi:10.1002/cam4.3652 · Cited by 13
Self-citation
Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission
Tien, F., Tsai, C., Huang, S.-C., Liu, J., Chen, C., Kuo, Y., Chuang, Y., Tseng, M., Peng, Y., Liu, M.-C., et al. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01454-z · Cited by 13
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
Biavasco, F., & Zeiser, R. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03352-6 · Cited by 12
JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms
Maslah, N., Kaci, N., Roux, B., Alexe, G., Marie, R., Pasquer, H., Verger, E., Oliveira, R. D. D., Culeux, C., Mlayah, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60884-1 · Cited by 16
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML
Popescu, B., Jones, M. F., Piao, M., Tran, E., Koh, A., Lomeli, I., Peretz, C. A. C., Murad, N. F., Abelson, S., Morales, C. E., et al. (2025) · Blood · doi:10.1182/blood.2025030558 · Cited by 16
Self-citation

Authors: McMahon, C. M., Ferng, T., Canaani, J., Wang, E. S., Morrissette, J. J. D., Eastburn, D. J., Pellegrino, M., Durruthy-Durruthy, R., Watt, C. D., Asthana, S., Lasater, E. A., DeFilippis, R., Peretz, C. A. C., McGary, L. H. F., Deihimi, S., Logan, A. C., Luger, S. M., Shah, N. P., Carroll, M., Smith, C. C., & Perl, A. E.
Affiliations: University of Pennsylvania (US)
University of California, San Francisco (US)
Tel Aviv University (IL)
Roswell Park Comprehensive Cancer Center (US)
Mission Bio (United States) (US)
United States Department of Veterans Affairs (US)
ORCID: McMahon, Christine M.
Ferng, Timothy
Canaani, Jonathan
Wang, Eunice S.
Morrissette, Jennifer J.D.
Eastburn, Dennis J.
Pellegrino, Maurizio
DeFilippis, RosaAnna
Peretz, Cheryl A.C.
McGary, Lisa H.F.
Logan, Aaron C.
Luger, Selina M.
Shah, Neil P.
Carroll, Martin
Smith, Catherine C.
Perl, Alexander E.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2019-08-01
Volume: 9
Issue: 8
Pages: 1050-1063
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-18-1453
PMC: PMC11994087
OpenAlex: W2946259536
Cited by: 446
References: 35
Citations by year: 2026: 35 · 2025: 55 · 2024: 56 · 2023: 62 · 2022: 91 · 2021: 61 · 2020: 68 · 2019: 16
FWCI: 41.51
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: HHS | NIH | National Center for Advancing Translational SciencesHHS | NIH | National Center for Advancing Translational Sciences (NCATS) (TL1TR001880)
American Society of Clinical OncologyAmerican Society of Clinical Oncology (ASCO)
HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (R21 CA198621, R01 CA198089, R01 CA166616, K08 CA187577)
Damon Runyon Cancer Research FoundationDamon Runyon Cancer Research Foundation (Damon Runyon) (CI-99-18)
Biff Ruttenberg Foundation
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
Keywords: acute myeloid leukemia, FLT3 mutation, gilteritinib, FLT3 inhibitor resistance, clonal selection, clonal evolution, NRAS mutation, KRAS mutation, BCR-ABL fusion gene, tyrosine kinase inhibitor resistance, single-cell DNA sequencing
MeSH terms: Adult, Aged, Aged, 80 and over, Aniline Compounds, Female, Humans, Male, Middle Aged, Mutation, Pyrazines, Signal Transduction, Leukemia, Myeloid, Acute, ras Proteins, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, fms-Like Tyrosine Kinase 3, Young Adult, Single-Cell Analysis, High-Throughput Nucleotide Sequencing, Clonal Evolution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks